205 related articles for article (PubMed ID: 22457212)
1. Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b.
Karlou M; Lu JF; Wu G; Maity S; Tzelepi V; Navone NM; Hoang A; Logothetis CJ; Efstathiou E
Prostate; 2012 Nov; 72(15):1638-47. PubMed ID: 22457212
[TBL] [Abstract][Full Text] [Related]
2. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
Ibuki N; Ghaffari M; Pandey M; Iu I; Fazli L; Kashiwagi M; Tojo H; Nakanishi O; Gleave ME; Cox ME
Int J Cancer; 2013 Oct; 133(8):1955-66. PubMed ID: 23564295
[TBL] [Abstract][Full Text] [Related]
3. BMP4 promotes prostate tumor growth in bone through osteogenesis.
Lee YC; Cheng CJ; Bilen MA; Lu JF; Satcher RL; Yu-Lee LY; Gallick GE; Maity SN; Lin SH
Cancer Res; 2011 Aug; 71(15):5194-203. PubMed ID: 21670081
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer.
Mimeault M; Rachagani S; Muniyan S; Seshacharyulu P; Johansson SL; Datta K; Lin MF; Batra SK
Oncotarget; 2015 Feb; 6(6):3887-903. PubMed ID: 25682877
[TBL] [Abstract][Full Text] [Related]
5. Exogenous hedgehog antagonist delays but does not prevent fracture healing in young mice.
Liu X; McKenzie JA; Maschhoff CW; Gardner MJ; Silva MJ
Bone; 2017 Oct; 103():241-251. PubMed ID: 28734986
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors.
Benvenuto M; Masuelli L; De Smaele E; Fantini M; Mattera R; Cucchi D; Bonanno E; Di Stefano E; Frajese GV; Orlandi A; Screpanti I; Gulino A; Modesti A; Bei R
Oncotarget; 2016 Feb; 7(8):9250-70. PubMed ID: 26843616
[TBL] [Abstract][Full Text] [Related]
7. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
[TBL] [Abstract][Full Text] [Related]
8. Hedgehog signaling mediates woven bone formation and vascularization during stress fracture healing.
Kazmers NH; McKenzie JA; Shen TS; Long F; Silva MJ
Bone; 2015 Dec; 81():524-532. PubMed ID: 26348666
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the hedgehog pathway targets the tumor-associated stroma in pancreatic cancer.
Hwang RF; Moore TT; Hattersley MM; Scarpitti M; Yang B; Devereaux E; Ramachandran V; Arumugam T; Ji B; Logsdon CD; Brown JL; Godin R
Mol Cancer Res; 2012 Sep; 10(9):1147-57. PubMed ID: 22859707
[TBL] [Abstract][Full Text] [Related]
10. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.
Ramaswamy B; Lu Y; Teng KY; Nuovo G; Li X; Shapiro CL; Majumder S
Cancer Res; 2012 Oct; 72(19):5048-59. PubMed ID: 22875023
[TBL] [Abstract][Full Text] [Related]
11. Vismodegib.
Meiss F; Andrlová H; Zeiser R
Recent Results Cancer Res; 2018; 211():125-139. PubMed ID: 30069764
[TBL] [Abstract][Full Text] [Related]
12. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma.
Kim EJ; Sahai V; Abel EV; Griffith KA; Greenson JK; Takebe N; Khan GN; Blau JL; Craig R; Balis UG; Zalupski MM; Simeone DM
Clin Cancer Res; 2014 Dec; 20(23):5937-5945. PubMed ID: 25278454
[TBL] [Abstract][Full Text] [Related]
13. Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers.
Efstathiou E; Karlou M; Wen S; Hoang A; Pettaway CA; Pisters LL; Maity S; Troncoso P; Logothetis CJ
Prostate; 2013 Jan; 73(2):153-61. PubMed ID: 22753310
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.
LoRusso PM; Rudin CM; Reddy JC; Tibes R; Weiss GJ; Borad MJ; Hann CL; Brahmer JR; Chang I; Darbonne WC; Graham RA; Zerivitz KL; Low JA; Von Hoff DD
Clin Cancer Res; 2011 Apr; 17(8):2502-11. PubMed ID: 21300762
[TBL] [Abstract][Full Text] [Related]
15. Smoothened is a poor prognosis factor and a potential therapeutic target in glioma.
Tu Y; Niu M; Xie P; Yue C; Liu N; Qi Z; Gao S; Liu H; Shi Q; Yu R; Liu X
Sci Rep; 2017 Feb; 7():42630. PubMed ID: 28195165
[TBL] [Abstract][Full Text] [Related]
16. β
Zhang M; Wang Q; Sun X; Yin Q; Chen J; Xu L; Xu C
Prostate; 2020 Nov; 80(15):1328-1340. PubMed ID: 32894788
[TBL] [Abstract][Full Text] [Related]
17. Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma.
Meerang M; Bérard K; Felley-Bosco E; Lauk O; Vrugt B; Boss A; Kenkel D; Broggini-Tenzer A; Stahel RA; Arni S; Weder W; Opitz I
Mol Cancer Ther; 2016 May; 15(5):1095-105. PubMed ID: 26839306
[TBL] [Abstract][Full Text] [Related]
18. Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers.
Li QR; Zhao H; Zhang XS; Lang H; Yu K
Acta Pharmacol Sin; 2019 Feb; 40(2):257-267. PubMed ID: 29777201
[TBL] [Abstract][Full Text] [Related]
19. Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer.
Lee YC; Lin SC; Yu G; Cheng CJ; Liu B; Liu HC; Hawke DH; Parikh NU; Varkaris A; Corn P; Logothetis C; Satcher RL; Yu-Lee LY; Gallick GE; Lin SH
Cancer Res; 2015 Nov; 75(22):4949-59. PubMed ID: 26530902
[TBL] [Abstract][Full Text] [Related]
20. Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms.
Singh BN; Fu J; Srivastava RK; Shankar S
PLoS One; 2011; 6(11):e27306. PubMed ID: 22087285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
